To investigate whether these effects induced by aT-sEVs were associated with PD-1/CD80 on sEVs, anti-PD-1 and anti-CD80 antibodies were used to block PD-1 and CD80 on aT-sEVs before treating tumour cells. Here, PDCD1 is linked to neoplasm.